<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="2145b392-7aac-44c6-83fd-3a9d88837167"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use PHYTONADIONE TABLETS safely and effectively. See full prescribing information for PHYTONADIONE TABLETS.<br/>
      <br/>PHYTONADIONE tablets, for oral use <br/>Initial U.S. Approval: 1955</title>
   <effectiveTime value="20250303"/>
   <setId root="54f23bc8-d8f3-40e8-a93d-3121cc581d54"/>
   <versionNumber value="5"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="191427277" root="1.3.6.1.4.1.519.1"/>
            <name>Major Pharmaceuticals</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="815739b4-764b-4fa8-93c6-56c58c223db8"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20211018"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0904-6882" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Phytonadione</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Phytonadione</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="69238-1051" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="5"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="A034SE7857" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PHYTONADIONE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="A034SE7857" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>PHYTONADIONE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ID3K20OAXF" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ACACIELLA ANGUSTISSIMA BARK</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="L11K75P92J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ANHYDROUS DIBASIC CALCIUM PHOSPHATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="20"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0904-6882-10" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20180515"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA209373" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20180515"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="YELLOW" xsi:type="CE">
                              <originalText>Light yellow to yellow</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="6" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="2" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">AA;05</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="LINK_48a0e91b-f312-4b7b-8793-a4243b21b18a">
               <id root="350193f0-598c-490e-a742-8081e911c635"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Phytonadione tablets are indicated for the treatment of adults with the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity.</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Anticoagulant-induced hypoprothrombinemia caused by coumarin or indanedione derivatives. </item>
                     <item>
                        <caption>•</caption>Hypoprothrombinemia secondary to antibacterial therapy. </item>
                     <item>
                        <caption>•</caption>Hypoprothrombinemia secondary to factors limiting absorpsion or synthesis of vitamin K, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancrease, and regional enteritis.</item>
                     <item>
                        <caption>•</caption>Other drug-induced hypoprothrombinemia where it is definitely shown that the result is due to interference with vitamin K metabolism, e.g., salicylates.</item>
                  </list>
               </text>
               <effectiveTime value="20241209"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Phytonadione is a vitamin K replacement indicated for the treatment of adults with the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity:</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives. <linkHtml href="#_RefLINK_48a0e91b-f312-4b7b-8793-a4243b2">(1)</linkHtml>
                           </item>
                           <item>
                              <caption>•</caption>Hypoprothrombinemia secondary to antibacterial therapy. <linkHtml href="#_RefLINK_48a0e91b-f312-4b7b-8793-a4243b2">(1)</linkHtml>
                           </item>
                           <item>
                              <caption>•</caption>Hypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin K, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, and regional enteritis. <linkHtml href="#_RefLINK_48a0e91b-f312-4b7b-8793-a4243b2">(1)</linkHtml>
                           </item>
                           <item>
                              <caption>•</caption>Other drug-induced hypoprothrombinemia where it is definitively shown that the result is due to interference with vitamin K metabolism, e.g., salicylates. <linkHtml href="#_RefLINK_48a0e91b-f312-4b7b-8793-a4243b2">(1)</linkHtml>
                              <br/>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_1ac300b1-ede1-4e26-9636-5af2ec1aa9c9">
               <id root="3261ae5d-2b44-42b4-8593-03ec4ef700c2"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20241209"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Anticoagulant-Induced Prothrombin Deficiency: 2.5 mg to 10 mg or up to 25 mg. <linkHtml href="#LINK_757ee61e-4b8f-40b5-8866-6b7cc6930ec4">(2.2)</linkHtml> </item>
                           <item>
                              <caption>•</caption>Hypoprothrombinemia Due to Other Causes: 2.5 mg to 25 mg or more. <linkHtml href="#LINK_757ee61e-4b8f-40b5-8866-6b7cc6930ec4">(2.2)</linkHtml>
                           </item>
                           <item>
                              <caption>•</caption>Must be given with bile salts when endogenous supply of bile to gastrointestinal track is deficient. <linkHtml href="#LINK_034ee3f1-2f6b-4214-9f35-b8741e9d4633">(2.1)</linkHtml>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_034ee3f1-2f6b-4214-9f35-b8741e9d4633">
                     <id root="afe801b6-66af-415b-928f-74ec9a4914d3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1    Dosing Considerations</title>
                     <text>
                        <paragraph>Avoid the oral route when the clinical disorder would prevent proper absorption. Bile salts must be given with the tablets when the endogenous supply of bile to the gastrointestinal tract is deficient. The coagulant effects of phytonadione tablets are not immediate; improvement of international normalized ratio (INR) may take 1 to 8 hours. Interim use of whole blood or component therapy may also be necessary if bleeding is severe.</paragraph>
                        <paragraph>Phytonadione tablets will not counteract the anticoagulant action of heparin. </paragraph>
                        <paragraph> When phytonadione tablets are used to correct excessive anticoagulant-induced hypoprothrombinemia, anticoagulant therapy still being indicated, the patient is again faced with the clotting hazards existing prior to starting the anticoagulant therapy. Phytonadione tablets are not a clotting agent, but overzealous therapy with vitamin K1 may restore conditions which originally permitted thromboembolic phenomena. Dosage should be kept as low as possible, and prothrombin time should be checked regularly as clinical conditions indicate.</paragraph>
                     </text>
                     <effectiveTime value="20220607"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_757ee61e-4b8f-40b5-8866-6b7cc6930ec4">
                     <id root="a7ef554f-3180-452b-8c12-daa2612657f2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2    Recommended Dosage</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Anticoagulant-Induced Prothrombin Deficiency in Adults </content>
                        </paragraph>
                        <paragraph>The recommended dose to correct excessively prolonged prothrombin times caused by oral anticoagulant therapy is, 2.5 mg to 10 mg or up to 25 mg initially. In some instances 50 mg may be required. Frequency and amount of subsequent doses should be determined by prothrombin time response or clinical condition. If, in 12 to 48 hours after oral administration, the prothrombin time has not been shortened satisfactorily, repeat the dose. </paragraph>
                        <paragraph>Repeated large doses of phytonadione tablets are not warranted in liver disease if the response to initial use of the vitamin is unsatisfactory. Failure to respond to phytonadione may indicate a congenital coagulation defect or that the condition being treated is unresponsive to vitamin K. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Hypoprothrombinemia Due to Other Causes in Adults </content>
                        </paragraph>
                        <paragraph>If possible, discontinuation or reduction of the dosage of drugs interfering with coagulation mechanisms (such as salicylates, antibiotics) is suggested as an alternative to administering concurrent phytonadione tablets. The severity of the coagulation disorder should determine whether the immediate administration of phytonadione tablets are required in addition to discontinuation or reduction of interfering drugs. </paragraph>
                        <paragraph>The recommended dose is 2.5 mg to 25 mg or more (sometimes up to 50 mg). Evaluate INR after 6 to 8 hours, and repeat dose if INR remains prolonged. Modify subsequent dosage (amount and frequency) based upon the INR or clinical condition.</paragraph>
                     </text>
                     <effectiveTime value="20220607"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_ed9cc327-a9b2-497e-8154-bd9219fd4770">
               <id root="0dd5f2c8-e853-436a-8afe-27a55b724954"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Phytonadione tablets USP, 5 mg are light yellow to yellow colored, round, scored tablets, debossed with “AA” and “05” on either side of scoring and plain on the other side.</paragraph>
               </text>
               <effectiveTime value="20211018"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Tablets: 5 mg <linkHtml href="#_RefLINK_ed9cc327-a9b2-497e-8154-bd9219f">(3)</linkHtml>
                           <br/>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_7600ad47-5a2d-4055-b6a8-9334addd62c5">
               <id root="2eec03b0-4a2e-4673-8f8c-6b09bd896452"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Phytonadione tablets are contraindicated in patients with a history of a hypersensitivity reaction to phytonadione or inactive ingredients <content styleCode="italics">[see <linkHtml href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=54c1c1df-0e65-4da8-9023-6cbaa0f5bd0d">Description (</linkHtml>
                        <linkHtml href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=54c1c1df-0e65-4da8-9023-6cbaa0f5bd0d">11)</linkHtml>]</content>.</paragraph>
               </text>
               <effectiveTime value="20211018"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Hypersensitivity to any component of this medication. <linkHtml href="#_RefLINK_7600ad47-5a2d-4055-b6a8-9334add">(4)</linkHtml>
                           <br/>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_9440e503-baf7-441c-991f-439bc85d32c3">
               <id root="bdcb7393-1130-4448-8923-ba22ad657e6f"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following adverse reactions associated with the use of parenteral phytonadione were identified in clinical studies or post-marketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                  <paragraph>Severe hypersensitivity reactions, including anaphylactoid reactions and deaths, have been reported following parenteral administration. The majority of these reported events occurred following intravenous administration. </paragraph>
                  <paragraph>Transient “flushing sensations” and “peculiar” sensations of taste have been observed with parenteral phytonadione, as well as instances of dizziness, rapid and weak pulse, profuse sweating, brief hypotension, dyspnea, and cyanosis. </paragraph>
                  <paragraph>Hyperbilirubinemia has been observed in the newborn following administration of parenteral phytonadione. This has occurred primarily with doses above those recommended.</paragraph>
               </text>
               <effectiveTime value="20211018"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions are transient “flushing sensations”, “peculiar” sensations of taste and instances of dizziness, rapid and weak pulse, profuse sweating, brief hypotension, dyspnea, and cyanosis. <linkHtml href="#_RefLINK_9440e503-baf7-441c-991f-439bc85">(6)</linkHtml>
                           <br/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_502b69ea-bc62-44f2-99bf-3b1e2befd8e4">
               <id root="fb35bd6f-1582-4be9-9658-6f4e1c0a1891"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Anticoagulants </content>
                  </paragraph>
                  <paragraph>Phytonadione may induce temporary resistance to prothrombin-depressing anticoagulants, especially when larger doses of phytonadione are used. Should this occur, higher doses of anticoagulant therapy may be needed when resuming anticoagulant therapy or a change in therapy to a different class of anticoagulant may be necessary (i.e., heparin sodium).</paragraph>
                  <paragraph> Phytonadione does not affect the anticoagulant action of heparin.</paragraph>
               </text>
               <effectiveTime value="20211018"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Anticoagulants: May induce temporary resistance to prothrombin-depressing anticoagulants. <linkHtml href="#_RefLINK_502b69ea-bc62-44f2-99bf-3b1e2be">(7)</linkHtml>
                           <br/>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_d8fb27d1-edc0-46b8-9cc1-d87f6735066d">
               <id root="34028a45-c981-4939-b8be-843f0fdc7a11"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20241209"/>
               <component>
                  <section ID="LINK_c7ddff79-330d-427b-b47b-400ef0464579">
                     <id root="4b7e77db-cdd7-43bc-a00b-eef1c0ada8bf"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Risk Summary </content>
                           </content>
                        </paragraph>
                        <paragraph>Published studies with the use of phytonadione during pregnancy have not reported a clear association with phytonadione and adverse developmental outcomes <content styleCode="italics">[see <linkHtml href="#LINK_b5598356-a7c8-4106-ae1f-e06fae00c921">Data</linkHtml>]</content>. There are maternal and fetal risks associated with vitamin K deficiency during pregnancy <content styleCode="italics">[see <linkHtml href="#LINK_0c12d2d5-cfb4-46b5-b673-02463d315327">Clinical Considerations</linkHtml>]</content>. Animal reproduction studies have not been conducted with phytonadione. </paragraph>
                        <paragraph>The estimated background risk for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. </paragraph>
                     </text>
                     <effectiveTime value="20241209"/>
                     <component>
                        <section ID="LINK_0c12d2d5-cfb4-46b5-b673-02463d315327">
                           <id root="731d3573-c67e-4f4e-856f-b969a4eae0ca"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">
                                 <content styleCode="italics">Clinical Considerations</content>
                              </content>
                           </title>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Disease-associated maternal and/or embryo/fetal risk</content>
                              </paragraph>
                              <paragraph>Pregnant women with vitamin K deficiency hypoprothrombinemia may be at increased risk for bleeding diatheses during pregnancy and hemorrhagic events at delivery. Subclinical vitamin K deficiency during pregnancy has been implicated in rare cases of fetal intracranial hemorrhage.  </paragraph>
                           </text>
                           <effectiveTime value="20211018"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_b5598356-a7c8-4106-ae1f-e06fae00c921">
                           <id root="96744281-a44b-46ca-8b47-7efdfcf3440f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">
                                 <content styleCode="italics">Data</content>
                              </content>
                           </title>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Human Data</content>
                              </paragraph>
                              <paragraph>Phytonadione has been measured in cord blood of infants whose mothers were treated with phytonadione during pregnancy in concentrations lower than seen in maternal plasma. Administration of vitamin K1 to pregnant women shortly before delivery increased both maternal and cord blood concentrations. Published data do not report a clear association with phytonadione and adverse maternal or fetal outcomes when used during pregnancy. However, these studies cannot definitively establish the absence of any risk because of methodologic limitations including small sample size and lack of blinding.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Animal Data</content>
                              </paragraph>
                              <paragraph>In pregnant rats receiving vitamin K1 orally, fetal plasma and liver concentrations increased following administration, supporting placental transfer.</paragraph>
                           </text>
                           <effectiveTime value="20211018"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="LINK_b6a0645b-75e0-4d44-80e3-18b6b0e91f71">
                     <id root="a5d8d430-f468-4294-be8e-e33d7f392abf"/>
                     <code code="34079-4" codeSystem="2.16.840.1.113883.6.1" displayName="LABOR &amp; DELIVERY SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Risk Summary </content>
                           </content>
                        </paragraph>
                        <paragraph> Phytonadione is present in breastmilk. There are no data on the effects of phytonadione on the breastfed child or on milk production. The developmental and health benefits of breastfeeding should be considered along with the clinical need for phytonadione and any potential adverse effects on the breastfed child from phytonadione or from the underlying maternal condition.</paragraph>
                     </text>
                     <effectiveTime value="20220607"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_2a76746e-04aa-4ca6-8470-1aa0e68d79ac">
                     <id root="f7b771f9-18e3-446b-bfa4-d5bdf6c64cc0"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness in pediatric patients have not been established with phytonadione. Hemolysis, jaundice, and hyperbilirubinemia in newborns, particularly in premature infants, have been reported with vitamin K.</paragraph>
                     </text>
                     <effectiveTime value="20220607"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_1ba70efa-3f59-4ca4-bd18-d2b2f7217ba4">
                     <id root="defafaa8-194c-4eb2-88b3-48e8d8ccb956"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies of phytonadione did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</paragraph>
                     </text>
                     <effectiveTime value="20220607"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_94dfdaa6-3893-42c2-9260-ca4a11462f2f">
               <id root="fbbd438f-42cf-4388-ae19-77e435efe5a2"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Phytonadione is a vitamin K replacement, which is a clear, yellow to amber, very viscous, odorless or practically odourless liquid. It is soluble in dehydrated alcohol, benzene, chloroform and ether; slightly soluble in alcohol (96%) and insoluble in water. It has a molecular weight of 450.70 g/mol. </paragraph>
                  <paragraph>Phytonadione is 1,4-Naphthalenedione, 2-methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-,[R-[R*,R*-(E)]]. Its molecular formula is C<sub>31</sub>H<sub>46</sub>O<sub>2</sub> and its structural formula is:</paragraph>
                  <renderMultiMedia ID="id539" referencedObject="MM1"/>
                  <paragraph>Phytonadione tablets, USP for oral administration contain 5 mg of phytonadione, USP and are light yellow to yellow colored, round, scored tablets, debossed with “AA” and “05” on either side of scoring and plain on the other side. Inactive ingredients are acacia, anhydrous dibasic calcium phosphate, colloidal silicon dioxide, lactose monohydrate, magnesium stearate, pregelatinized starch, and talc.</paragraph>
               </text>
               <effectiveTime value="20211018"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>str</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="phytonadione-tablets-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_bccb04cc-3991-4ea2-b6f4-04a6afd0b8f3">
               <id root="210d573b-7ff2-4028-ab18-7449c324d482"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20211018"/>
               <component>
                  <section ID="LINK_f1abae1d-7871-43d7-bbb1-77ffe4b1ffb5">
                     <id root="064c644e-0b9f-40c7-a5ce-25aed1e56074"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Phytonadione tablets possess the same type and degree of activity as does naturally-occurring vitamin K, which is necessary for the production via the liver of active prothrombin (factor II), proconvertin (factor VII), plasma thromboplastin component (factor IX), and Stuart factor (factor X). The prothrombin test is sensitive to the levels of three of these four factors – II, VII, and X. Vitamin K is an essential cofactor for a microsomal enzyme that catalyzes the posttranslational carboxylation of multiple, specific, peptide-bound glutamic acid residues in inactive hepatic precursors of factors II, VII, IX, and X. The resulting gamma-carboxyglutamic acid residues convert the precursors into active coagulation factors that are subsequently secreted by liver cells into the blood. </paragraph>
                        <paragraph> In normal animals and humans, phytonadione is virtually devoid of pharmacodynamic activity. However, in animals and humans deficient in vitamin K, the pharmacological action of vitamin K is related to its normal physiological function, that is, to promote the hepatic biosynthesis of vitamin K-dependent clotting factors. </paragraph>
                     </text>
                     <effectiveTime value="20220607"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_4da84c96-3760-40e2-a939-5273202085ee">
                     <id root="6168d922-a188-40de-b4e0-049c5f6b89d9"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Phytonadione tablets generally exert their effect within 6 to 10 hours.</paragraph>
                     </text>
                     <effectiveTime value="20211018"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_40da22ab-9880-419c-aac4-3222230c217b">
                     <id root="3324c883-86b6-4b80-b940-c94743357954"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Absorption</content>
                           </content>
                        </paragraph>
                        <paragraph>Oral phytonadione is adequately absorbed from the gastrointestinal tract only if bile salts are present. </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Distribution </content>
                           </content>
                        </paragraph>
                        <paragraph>After absorption, phytonadione is initially concentrated in the liver, but the concentration declines rapidly. Very little vitamin K accumulates in tissues. </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Elimination </content>
                           </content>
                        </paragraph>
                        <paragraph> Little is known about the metabolic fate of vitamin K. Almost no free unmetabolized vitamin K appears in bile or urine.</paragraph>
                     </text>
                     <effectiveTime value="20220607"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_5daa79e6-a212-4003-bec5-c4661f04ac51">
               <id root="31c37954-93db-4af0-afaf-4c12da224500"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20220607"/>
               <component>
                  <section ID="LINK_de7b6a6c-102a-443a-8563-e9fb72cae2d9">
                     <id root="9ccb8125-5672-432e-9498-da5541298f0f"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Studies of carcinogenicity or impairment of fertility have not been performed with phytonadione. Phytonadione at concentrations up to 2,000 mcg/plate, with or without metabolic activation, was negative in the Ames microbial mutagen test.</paragraph>
                     </text>
                     <effectiveTime value="20220607"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_a0b45d85-af35-4ea1-b85b-0827eb4c813b">
               <id root="bf5a9f32-f428-4c64-831e-824f59088743"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Phytonadione Tablets USP, 5 mg are supplied as light yellow to yellow colored, round, scored tablets, debossed with “AA” and “05” on either side of scoring and plain on the other side.</paragraph>
                  <paragraph>They are available:</paragraph>
                  <paragraph>Cartons of 20 tablets (10 tablets each blister pack x 2), NDC 0904-6882-10</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Storage </content>
                     </content>
                  </paragraph>
                  <paragraph>Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. </paragraph>
                  <paragraph>Always protect phytonadione tablets, USP from light. </paragraph>
                  <paragraph> Store in tightly closed original container and carton until contents have been used.</paragraph>
               </text>
               <effectiveTime value="20241209"/>
            </section>
         </component>
         <component>
            <section ID="LINK_7f1499bb-6eb0-433e-ad99-1e4cdeab02da">
               <id root="efd4f1e5-afaf-4084-9d8e-28b951cfc618"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Vitamin K1 is fairly rapidly degraded by light; therefore, advise patients to always protect phytonadione tablets from light. Store phytonadione tablets in closed original carton until contents have been used <content styleCode="italics">[see <linkHtml href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=54c1c1df-0e65-4da8-9023-6cbaa0f5bd0d">How Supplied/Storage and Handling (16)</linkHtml>]</content>. </paragraph>
                  <paragraph>Manufactured by:<br/>
                     <content styleCode="bold">Amneal Pharmaceuticals Pvt. Ltd.</content>
                     <br/>
                     <content styleCode="bold">Oral Solid Dosage Unit</content>
                     <br/>Ahmedabad 382213, INDIA</paragraph>
                  <paragraph>Distributed by:<br/>
                     <content styleCode="bold">Amneal Pharmaceuticals LLC</content>
                     <br/>Bridgewater, NJ 08807 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Packaged and Distributed by:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">MAJOR® PHARMACEUTICALS</content>
                  </paragraph>
                  <paragraph>Indianapolis, IN 46268 USA</paragraph>
                  <paragraph>Refer to package label for Distributor's NDC Number</paragraph>
                  <paragraph>Rev. 10-2021-01</paragraph>
               </text>
               <effectiveTime value="20211018"/>
            </section>
         </component>
         <component>
            <section ID="ID_b4e22efe-cadc-4cf2-b8dd-6d8fe0e217f1">
               <id root="b0d7396c-354c-4fdf-8823-332dacb59006"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>Package/Label Display Panel </title>
               <text>
                  <paragraph>MAJOR®</paragraph>
                  <paragraph>NDC 0904-6882-10</paragraph>
                  <paragraph>Unit Dose</paragraph>
                  <paragraph>
                     <content styleCode="bold">Phytonadione</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Tablets, USP</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">5 mg</content>
                  </paragraph>
                  <paragraph>20 TABLETS (2 x 10)</paragraph>
                  <paragraph>Rx only</paragraph>
                  <renderMultiMedia ID="id1224408855" referencedObject="ID_7db3ca95-9d1d-4620-9ed5-77f4c240b813"/>
               </text>
               <effectiveTime value="20241209"/>
               <component>
                  <observationMedia ID="ID_7db3ca95-9d1d-4620-9ed5-77f4c240b813">
                     <text>5mg carton label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="94d89db9-981d-4fc5-b6fe-5d4b73230e35-00.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>